See up to 3 months of AKTS. The 7-day demo opens the 1M and 3M ranges and puts AKTS on your watchlist.
Start 7-day demoLatest AKTS insider trades
About Aktis Oncology, Inc. (AKTS)
Aktis Oncology, Inc. is an SEC registrant, filing under CIK 0002035832, classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector. Its offering priced on 9 January 2026 and it trades on NASDAQ.
AKTS Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 5 | 20,421 | $455K |
| Option exercise | 8 | 40,842 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
AKTS insider transactions (Form 4)
7613 Form 4 filings on record, the earliest from Jan 12, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Akos Czibere - Officer | Option exercise | Common Stock | 12,500 | $4.95 | $62K | |
| Akos Czibere - Officer | Open-market sale | Common Stock | 5,099 | $20.19 footnote F2 | $103K | |
| Akos Czibere - Officer | Open-market sale | Common Stock | 7,401 | $21.03 footnote F3 | $156K | |
| Akos Czibere - Officer | Option exercise | Stock Option (Right to Buy) | 12,500 | $0.00 | - | |
| ||||||
| Ken Herrmann | Option exercise | Common Stock | 3,506 | $0.08 | $280 | |
| Ken Herrmann | Option exercise | Common Stock | 1,350 | $1.91 | $3K | |
| Ken Herrmann | Open-market sale | Common Stock | 3,506 | $24.56 footnote F1 | $86K | |
| Ken Herrmann | Open-market sale | Common Stock | 1,350 | $24.56 footnote F1 | $33K | |
| Ken Herrmann | Option exercise | Stock Option (Right to Buy) | 3,506 | $0.00 | - | |
| Ken Herrmann | Option exercise | Stock Option (Right to Buy) | 1,350 | $0.00 | - | |
| ||||||
| Ken Herrmann | Option exercise | Common Stock | 3,065 | $0.08 | $245 | |
| Ken Herrmann | Open-market sale | Common Stock | 3,065 | $25.21 footnote F1 | $77K | |
| Ken Herrmann | Option exercise | Stock Option (Right to Buy) | 3,065 | $0.00 | - | |
| ||||||
| Shulamit Ron-Bigger - Officer | Option exercise | Common Stock | 50,000 | $3.66 | $183K | |
| Shulamit Ron-Bigger - Officer | Open-market sale | Common Stock | 15,800 | $27.13 footnote F1 | $429K | |
| Shulamit Ron-Bigger - Officer | Open-market sale | Common Stock | 30,000 | $27.94 footnote F2 | $838K | |
| Shulamit Ron-Bigger - Officer | Open-market sale | Common Stock | 4,200 | $28.75 footnote F3 | $121K | |
| Shulamit Ron-Bigger - Officer | Option exercise | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| ||||||
| Akos Czibere - Officer | Option exercise | Common Stock | 50,000 | $4.95 | $248K | |
| Akos Czibere - Officer | Open-market sale | Common Stock | 14,800 | $27.13 footnote F1 | $401K | |
| Akos Czibere - Officer | Open-market sale | Common Stock | 30,829 | $27.95 footnote F2 | $862K | |
| Akos Czibere - Officer | Open-market sale | Common Stock | 4,371 | $28.71 footnote F3 | $125K | |
| Akos Czibere - Officer | Option exercise | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| ||||||
| Glenn Gormley | Grant or award | Stock Option (Right to Buy) | 37,866 | $0.00 | - | |
 Todd Foley | Other | Common Stock | 597,391 footnote F1 | - footnote F2 | - | |
| Todd Foley | Other | Common Stock | 2,688,270 footnote F5 | - footnote F2 | - | |
| Todd Foley | Other | Common Stock | 716,872 footnote F7 | - footnote F2 | - | |
| Todd Foley | Open-market purchase | Common Stock | 232,870 footnote F9 | $18.00 | $4.19M | |
| Todd Foley | Other | Series Seed Redeemable Convertible Preferred Stock | 2,272,727 | $0.00 footnote F2 | - | |
| Todd Foley | Other | Series A Redeemable Convertible Preferred Stock | 10,227,273 | $0.00 footnote F2 | - | |
| Todd Foley | Other | Series B Redeemable Convertible Preferred Stock | 2,727,273 | $0.00 footnote F2 | - | |
| ||||||
| MPM BIOVENTURES 2018, L.P. | Other | Common Stock | 1,314,262 footnote F1 | - footnote F2 | - | |
| MPM BIOVENTURES 2018, L.P. | Other | Common Stock | 5,914,197 footnote F5 | - footnote F2 | - | |
| MPM BIOVENTURES 2018, L.P. | Other | Common Stock | 1,577,119 footnote F7 | - footnote F2 | - | |
| MPM BIOVENTURES 2018, L.P. | Open-market purchase | Common Stock | 1,112,777 footnote F9 | $18.00 | $20.03M | |
| MPM BIOVENTURES 2018, L.P. | Other | Series Seed Redeemable Convertible Preferred Stock | 5,000,000 | $0.00 footnote F2 | - | |
| MPM BIOVENTURES 2018, L.P. | Other | Series A Redeemable Convertible Preferred Stock | 22,500,000 | $0.00 footnote F2 | - | |
| MPM BIOVENTURES 2018, L.P. | Other | Series B Redeemable Convertible Preferred Stock | 6,000,000 | $0.00 footnote F2 | - | |
| ||||||
| Ansbert Gadicke | Other | Common Stock | 1,314,262 footnote F1 | - footnote F2 | - | |
| Ansbert Gadicke | Other | Common Stock | 5,914,197 footnote F5 | - footnote F2 | - | |
| Ansbert Gadicke | Other | Common Stock | 1,577,119 footnote F7 | - footnote F2 | - | |
| Ansbert Gadicke | Open-market purchase | Common Stock | 1,112,777 footnote F9 | $18.00 | $20.03M | |
| Ansbert Gadicke | Other | Series Seed Redeemable Convertible Preferred Stock | 5,000,000 | $0.00 footnote F2 | - | |
| Ansbert Gadicke | Other | Series A Redeemable Convertible Preferred Stock | 22,500,000 | $0.00 footnote F2 | - | |
| Ansbert Gadicke | Other | Series B Redeemable Convertible Preferred Stock | 6,000,000 | $0.00 footnote F2 | - | |
| ||||||
| EcoR1 Capital, LLC - Director | Other | Common Stock | 2,270,879 | - footnote F1 | - | |
| EcoR1 Capital, LLC - Director | Other | Common Stock | 202,862 | - footnote F1 | - | |
| EcoR1 Capital, LLC - Director | Open-market purchase | Common Stock | 2,077,779 | $18.00 | $37.40M | |
| EcoR1 Capital, LLC - Director | Other | Common Stock | 128,506 | - footnote F1 | - | |
| EcoR1 Capital, LLC - Director | Open-market purchase | Common Stock | 144,443 | $18.00 | $2.60M | |
| EcoR1 Capital, LLC - Director | Other | Series A Redeemable Convertible Preferred Stock | 9,913,810 | - footnote F1 | - | |
| EcoR1 Capital, LLC - Director | Other | Series A Redeemable Convertible Preferred Stock | 997,299 | - footnote F1 | - | |
| EcoR1 Capital, LLC - Director | Other | Series A Redeemable Convertible Preferred Stock | 488,891 | - footnote F1 | - | |
| EcoR1 Capital, LLC - Director | Other | Series B Redeemable Convertible Preferred Stock | 2,397,500 | - footnote F1 | - | |
| EcoR1 Capital, LLC - Director | Other | Series B Redeemable Convertible Preferred Stock | 102,500 | - footnote F1 | - | |
| EcoR1 Capital, LLC - Director | Other | Class A Common Stock | 965,190 | - footnote F1 | - | |
| EcoR1 Capital, LLC - Director | Other | Class A Common Stock | 86,222 | - footnote F1 | - | |
| ||||||
| Vida Ventures II, LLC | Other | Common Stock | 4,859,370 | - footnote F1 | - | |
| Vida Ventures II, LLC | Open-market purchase | Common Stock | 812,455 | $18.00 | $14.62M | |
| Vida Ventures II, LLC | Open-market purchase | Common Stock | 22,545 | $18.00 | $406K | |
| Vida Ventures II, LLC | Other | Common Stock | 134,842 | - footnote F1 | - | |
| Vida Ventures II, LLC | Other | Series A Redeemable Convertible Preferred Stock | 14,838,250 | $0.00 | - | |
| Vida Ventures II, LLC | Other | Series A Redeemable Convertible Preferred Stock | 411,750 | $0.00 | - | |
| Vida Ventures II, LLC | Other | Series B Redeemable Convertible Preferred Stock | 3,648,750 | $0.00 | - | |
| Vida Ventures II, LLC | Other | Series B Redeemable Convertible Preferred Stock | 101,250 | $0.00 | - | |
| ||||||
 Helen Susan Kim | Other | Common Stock | 4,859,370 | - footnote F1 | - | |
| Helen Susan Kim | Open-market purchase | Common Stock | 812,455 | $18.00 | $14.62M | |
| Helen Susan Kim | Other | Common Stock | 134,842 | - footnote F1 | - | |
| Helen Susan Kim | Open-market purchase | Common Stock | 22,545 | $18.00 | $406K | |
| Helen Susan Kim | Other | Series A Redeemable Convertible Preferred Stock | 14,838,250 | $0.00 | - | |
| Helen Susan Kim | Other | Series A Redeemable Convertible Preferred Stock | 411,750 | $0.00 | - | |
| Helen Susan Kim | Other | Series B Redeemable Convertible Preferred Stock | 3,648,750 | $0.00 | - | |
| Helen Susan Kim | Other | Series B Redeemable Convertible Preferred Stock | 101,250 | $0.00 | - | |
| ||||||
 Lloyd Mitchell Segal | Other | Common Stock | 19,631 | - footnote F1 | - | |
| Lloyd Mitchell Segal | Other | Series A Redeemable Convertible Preferred Stock | 50,000 | $0.00 | - | |
| Lloyd Mitchell Segal | Other | Series B Redeemable Convertible Preferred Stock | 24,687 | $0.00 | - | |
| ||||||
Item 2.02, 9.01
Item 2.02, 9.01
Item 5.02, 7.01, 9.01
Item 2.02, 9.01
Recent AKTS Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Akos Czibere | Officer | 25,000 | $553K | View on EDGAR | |
| - | - | - | - |
AKTS insider trading FAQ
What is the latest insider trade for AKTS?
Aktis Oncology, Inc. (AKTS) had 3 insider filings in the last 90 days, with the most recent on 2026-09-24. The full record for AKTS runs to 13 Form 4 filings, the earliest from 2026-01-12. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying AKTS stock?
No insider purchases of AKTS were filed in the last 90 days. 9 purchases are on record for this company.
How many insiders are selling AKTS stock?
5 insider sales of AKTS were filed in the last 90 days, totaling $455K.
Where can I see AKTS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects AKTS Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Akos Czibere view on EDGAR
- - Ken Herrmann view on EDGAR
- - Ken Herrmann view on EDGAR
- - Shulamit Ron-Bigger view on EDGAR
- - Akos Czibere view on EDGAR
- - Glenn Gormley view on EDGAR
- - Todd Foley view on EDGAR
- - MPM BIOVENTURES 2018, L.P. view on EDGAR
- - Ansbert Gadicke view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where AKTS's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow AKTS with a 7-day demo
- AKTS on your watchlist
- Every AKTS Form 4 filing on record
- Up to 3 months of AKTS price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
